Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01541319 · ClinicalTrials.gov registry record
Mechanism and Repository Study for the Red Cell Storage Duration Study
A clinical trial, sponsored by Carelon Research.
- Completed
- Registry status
- 92
- Enrollment target
NCT01541319 is a clinical trial that has completed, run by Carelon Research. The registered enrollment target is 92 participants.
The verdict
NCT01541319 has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
Study Summary
A large multicenter randomized controlled trial of approximately 1700 critically ill patients' status post complex cardiac surgery with sternotomy, called the Red Cell Storage Duration Study (RECESS), is currently ongoing. In the RECESS trial, study groups are randomized to either RBCs of less than or equal to 10 days storage time or to greater than or equal to 21 days. The primary outcome of RECESS is a change in multiple organ dysfunction score. Secondary outcomes in RECESS include all cause 28-day mortality, mechanical ventilation free days, and other clinical outcomes. The RECESS study presents a unique opportunity to investigate mechanisms associated with RBC storage duration in the context of clinical outcomes for well-characterized surgical study groups. The ancillary study described here is called the Mechanism and Repository Study (MARS) for RECESS. The MARS study will analyze the most commonly reported and hypothesized mechanisms considered to be associated with the RBC storage lesion and adverse outcomes in critically ill patients. Laboratories with expertise in RBC function, nitric oxide mechanisms, the coagulation cascade, microparticle analysis and immunology will each examine hypotheses addressing mechanisms potentially able to relate storage time to clinical outcomes in RBC transfusion recipients. At the conclusion of the study, the results will provide a much better understanding of how RBC storage age affects recipient RBC function, coagulation parameters, microparticle load and immune modulation. Perhaps most importantly, this study will also develop a large sample repository for future analysis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01541319
The ClinicalTrials.gov registry entry for NCT01541319 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01541319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01541319 about?
NCT01541319 is a clinical study titled "Mechanism and Repository Study for the Red Cell Storage Duration Study". A large multicenter randomized controlled trial of approximately 1700 critically ill patients' status post complex cardiac surgery with sternotomy, called the Red Cell Storage Duration Study (RECESS), is currently ongoing. In the RECESS trial, study groups are randomized to either RBCs of less than ...
What is the current status of trial NCT01541319?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2012-07. Estimated completion is 2016-08.
Who is sponsoring clinical trial NCT01541319?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.